content_top
34 companies, 1 interpreter! Insight, foresight
and recommendation 

Cytori Therapeutics, Inc. (CYTX)

0
0.03
(11.22%)
 Sep 11, 4:00PM EDT
content_middle

Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions.

CYTX primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma.

CYTX offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.

CYTX also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer.

The company was founded in 1996 and is headquartered in San Diego, California.

Company Website
Previous Close: 
0.37
Open: 
0.38
Bid: 
0.29
Ask: 
0.40
1yr Target Price: 
2.17
Day's Range: 
0.36 - 0.40
52wk Range: 
0.21 - 2.32
Volume: 
575928
Average Daily Volume: 
817471
Market Capitalization: 
5.49M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
22.16M
content_right

Pages